Indian drugmaker Dr Reddy’s Laboratories (NYSE: RDY) has seen its profits plummet for the most recent quarter by 85.9% compared to the same period a year ago.
The company lost $64.7 million in the fourth quarter ended March 31, 216, because the government of financially struggling Venezuela has not approved to repatriate any amount beyond $4 million dollars owed to Dr Reddy’s.
As well as announcing its results for the last quarter, Dr Reddy’s has revealed its figures for the last financial year, which show a 4% rise in consolidated revenues to $2.34 billion. The $302 million profit made in the year, bringing diluted earnings per share (EPS) of $1.77, is a 10% increase on the financial year which ended in March 2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze